trans-Stilbenoids: potent and selective inhibitors for human cytochrome P450 1B1

On the basis of our previous insights into the structural requirements of stilbenoids for the inhibition of cytochrome P450 1B1 (CYP1B1), a series of 2,4-dimethoxy group-containing stilbenes was prepared and evaluated for their inhibitory effects on the activity of CYP1s with the ultimate goal of identifying a potent and selective CYP1B1 inhibitor. Among the thirteen derivatives prepared, five compounds exhibited similar or greater potency compared to the previous lead compound, 2,4,3′,5′-tetramethoxystilbene (2,4,3′,5′-TMS), in inhibiting CYP1B1. In particular, 2,2′,3′,4,6′-pentamethoxystilbene was found to be a more selective and more potent CYP1B1 inhibitor than 2,4,3′,5′-TMS. 2,4,2′,6′-TMS showed remarkably potent inhibitory activity against CYP1B1 (IC50 = 1.77 ± 0.14 nM) and also had a very high selectivity toward CYP1 isoenzymes. Molecular modeling was performed to determine the key molecular interactions with the CYP1B1 and CYP1A2 structures. On the basis of these structural and biological studies, the design of more potent and more selective drug-like derivatives can be envisaged.

[1]  T. Itoh,et al.  Selective inhibition of methoxyflavonoids on human CYP1B1 activity. , 2010, Bioorganic & medicinal chemistry.

[2]  R. Dahiya,et al.  Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. , 2009, Cancer research.

[3]  O. Hankinson,et al.  Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  N. Roodi,et al.  Estrogen Metabolism and Breast Cancer , 2009, Annals of the New York Academy of Sciences.

[5]  V. Vasiliou,et al.  Role of CYP1B1 in glaucoma. , 2008, Annual review of pharmacology and toxicology.

[6]  R. D. Bruno,et al.  Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. , 2007, Bioorganic & medicinal chemistry.

[7]  G. Fuller,et al.  Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target , 2007, Clinical Cancer Research.

[8]  C David Stout,et al.  Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.

[9]  W. Baer-Dubowska,et al.  Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. , 2007, Molecular nutrition & food research.

[10]  D. Nebert,et al.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.

[11]  Thomas K. H. Chang,et al.  Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. , 2006, Toxicology and applied pharmacology.

[12]  Y. Moon,et al.  Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[13]  A. Sparreboom,et al.  Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention , 2006, Molecular Cancer Research.

[14]  Y. Chun,et al.  MODULATION OF HUMAN CYTOCHROME P450 1B1 EXPRESSION BY 2,4,3′,5′-TETRAMETHOXYSTILBENE , 2005, Drug Metabolism and Disposition.

[15]  G. Murray,et al.  Cytochrome P450 1B1: a novel anticancer therapeutic target. , 2005, Future oncology.

[16]  R. Dahiya,et al.  Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer , 2005, Clinical Cancer Research.

[17]  N. Seeram,et al.  Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. , 2004, Anticancer research.

[18]  G. Murray,et al.  Cytochrome P450 enzymes: novel options for cancer therapeutics. , 2004, Molecular cancer therapeutics.

[19]  T. Shimada,et al.  Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1 , 2004, Cancer science.

[20]  Y. Chun,et al.  Discovery of cytochrome P450 1B1 inhibitors as new promising anti‐cancer agents , 2003, Medicinal research reviews.

[21]  Tsutomu Shimada,et al.  Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism. , 2003, Chemico-biological interactions.

[22]  T. Shimada,et al.  Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. , 2003, Mutation research.

[23]  A. Luch,et al.  Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. , 2002, Chemical research in toxicology.

[24]  L. Leung,et al.  Baicalein inhibits DMBA-DNA adduct formation by modulating CYP1A1 and CYP1B1 activities. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  Y. Chun,et al.  Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. , 2002, Journal of medicinal chemistry.

[26]  F. Guengerich,et al.  A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. , 2001, Cancer research.

[27]  H. McLeod,et al.  Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer , 2001, British Journal of Cancer.

[28]  T. Chang,et al.  Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. , 2000, Canadian journal of physiology and pharmacology.

[29]  F. Guengerich,et al.  Resveratrol is a selective human cytochrome P450 1A1 inhibitor. , 1999, Biochemical and biophysical research communications.

[30]  T. Shimada,et al.  Catalytic properties of polymorphic human cytochrome P450 1B1 variants. , 1999, Carcinogenesis.

[31]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J A McKay,et al.  Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.

[33]  N. Walker,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. F. Greenlee,et al.  Expression of cytochrome P450 CYP1B1 in breast cancer , 1995, FEBS letters.

[35]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.